Table 1.

Patient characteristics by treatment

  AllErlotinib (n = 59)Vandetanib (n = 54)Erlotinib + bexarotene (n = 37)Sorafenib (n = 105)
  n (%)n (%)n (%)n (%)n (%)
Age≤5041 (16%)5 (8%)11 (20%)6 (16%)19 (18%)
(mean, 62; range, 26–84)51–6073 (29%)23 (39%)15 (28%)11 (30%)24 (23%)
 61–7086 (34%)19 (32%)19 (35%)11 (30%)37 (35%)
 >7055 (22%)12 (20%)9 (17%)9 (24%)25 (24%)
GenderFemale118 (46%)26 (44%)29 (54%)12 (32%)51 (49%)
 Male137 (54%)33 (56%)25 (46%)25 (68%)54 (51%)
EthnicityCaucasian209 (82%)51 (86%)41 (76%)31 (84%)86 (82%)
 Hispanic16 (6%)2 (3%)7 (13%)0 (0%)7 (7%)
 African American16 (6%)3 (5%)2 (4%)4 (11%)7 (7%)
 Asian14 (5%)3 (5%)4 (7%)2 (5%)5 (5%)
SmokerCurrent23 (9%)9 (15%)5 (9%)3 (8%)6 (6%)
 Former177 (69%)41 (69%)31 (57%)32 (86%)73 (70%)
 Never55 (22%)9 (15%)18 (33%)2 (5%)26 (25%)
HistologyAdenocarcinoma160 (63%)31 (53%)35 (65%)23 (62%)71 (68%)
 Squamous46 (18%)16 (27%)7 (13%)6 (16%)20 (19%)
 Others49 (19%)12 (20%)12 (22%)8 (22%)14 (13%)
Prior erlotinib therapyNo139 (55%)59 (100%)9 (17%)37 (100%)34 (32%)
 Yes116 (45%)0 (0%)45 (83%)0 (0%)71 (68%)
ECOG performance status022 (9%)5 (8%)9 (17%)2 (5%)6 (6%)
 1197 (77%)44 (75%)36 (67%)30 (81%)87 (83%)
 236 (14%)10 (17%)9 (17%)5 (14%)12 (11%)
Prior cytotoxic chemotherapy195 (37%)25 (42%)21 (39%)18 (49%)31 (30%)
(median, 2; range, 1–6)284 (33%)20 (34%)17 (31%)12 (32%)35 (33%)
 340 (16%)9 (15%)7 (13%)4 (11%)20 (19%)
 424 (9%)4 (7%)6 (11%)2 (5%)12 (11%)
 59 (4%)1 (2%)2 (4%)1 (3%)5 (5%)
 63 (1%)0 (0%)1 (2%)0 (0%)2 (2%)